[Effects of estrogen, progestin and mifepristone on endometrial carcinoma cell lines].
OBJECTIVE
To study the effects of estrogen, progestogen and mifepristone on endometrial carcinoma cell lines in vitro.


METHODS
The well-differentiated endometrial cancer cell line Ishikawa and moderate-differentiated endometrial cancer cell line Hec-1B were cultured in vitro. The cells were divided into four groups: control, estrogen, estrogen and progestogen, estrogen and progestogen and mifepristone, then we implanted cells in 96-well plates to search the response in distinct hormones.


RESULTS
When stimulated by estrogen for 72 hours, the growth of Ishikawa cells was significantly higher than the control, Hec-1B cells only grew higher than the control, but it was no significance in statistics. Progestogen inhibited Ishikawa cells significantly after being stimulating for 72 hours, there was the same effect on Hec-1B cells after being stimulating for 96 hours. On the base of estrogen and progestogen, we added mifepristone, cells developed after 96 hours in Ishikawa cells and cells developed after 48 hours in Hec-1B cells.


CONCLUSIONS
Estrogen can cause endometrial carcinoma cell growth; progestogen inhibits the hyperplasia induced by estrogen; mifepristone antagonizes the effect of progestogen on cell growth.
Lu
Ye
Y
Department of Obstetrics & Gynecology, Peking University First Hospital, Beijing 100034, China.
Yu
Li
L
Chen
Chun-ling
CL
Liao
Qin-ping
QP
D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D016889:Endometrial Neoplasms / Q000473:pathology*; D004958:Estradiol / Q000494:pharmacology*; D005260:Female; D006801:Humans; D015735:Mifepristone / Q000494:pharmacology*; D011374:Progesterone / Q000494:pharmacology*; D014594:Uterine Neoplasms / Q000473:pathology*
D015735:Mifepristone; D011374:Progesterone; D004958:Estradiol